In a welcome move, QuidelOrtho saw its Relative Strength Rating rise from 70 to 74 on Monday.
IBD's proprietary rating identifies price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks often have an 80 or better RS Rating as they launch their biggest price moves. See if QuidelOrtho can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
QuidelOrtho is not currently showing a potential entry point. See if the stock goes on to build a base that could spark a new run.
Earnings growth fell in the most recent quarter from 0% to -6%. But revenue gains moved higher, from -4% to -2%. The company is expected to report its latest performance numbers on or around Feb. 12.
The company earns the No. 66 rank among its peers in the Medical-Products industry group. Globus Medical, Boston Scientific and Insulet are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
